Darren K McGuire
Overview
Explore the profile of Darren K McGuire including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
457
Citations
35025
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
El Khalili L, El Khalili L, Rawshani A, Boren J, Bhatt D, Gerstein H, et al.
Cardiovasc Diabetol
. 2025 Mar;
24(1):117.
PMID: 40075392
Objective: To investigate standardized incidence of atrial fibrillation (AF) in individuals with type 1 diabetes (T1DMM) compared with matched controls from the general population. Additionally, to examine optimal levels- and...
2.
Lee M, Ghouri N, Misra A, Kang Y, Rutter M, Gerstein H, et al.
Diabetes Care
. 2025 Feb;
48(3):489-493.
PMID: 39977628
Background: Cardiovascular outcome trials (CVOTs) suggest glucagon-like peptide 1 receptor agonists (GLP-1RAs) provide greater cardiovascular (CV) benefits in Asian compared with White individuals. Purpose: Compare CV efficacy of GLP-1RAs between...
3.
Aggarwal R, Bhatt D, Szarek M, Cannon C, Leiter L, Inzucchi S, et al.
Lancet Diabetes Endocrinol
. 2025 Feb;
PMID: 39961315
Background: Sodium-glucose co-transporter (SGLT)-2 inhibitors have shown consistent benefit in improving heart failure-related outcomes but not ischaemic cardiovascular events such as myocardial infarction or stroke. We assessed if the dual...
4.
Pandey A, Kolkailah A, McGuire D, Frederich R, Cater N, Cosentino F, et al.
Eur J Heart Fail
. 2025 Jan;
PMID: 39792342
Aims: In VERTIS CV, ertugliflozin was associated with a 30% risk reduction for adjudication-confirmed, first and total hospitalizations for heart failure (HHF) in participants with type 2 diabetes and atherosclerotic...
5.
Zannad F, McGuire D, Ortiz A
J Intern Med
. 2024 Dec;
PMID: 39739537
Chronic kidney disease (CKD) is a prevalent and progressive condition associated with significant mortality and morbidity. Diabetes is a common cause of CKD, and both diabetes and CKD increase the...
6.
Ambrosy A, Sauer A, Patel S, Windsor S, Borlaug B, Husain M, et al.
ESC Heart Fail
. 2024 Dec;
PMID: 39716939
Aims: Sodium-glucose co-transporter-2 (SGLT2) inhibitors improve health status and outcomes in the setting of heart failure (HF) across the range of ejection fraction (EF). Baseline kidney disease is common in...
7.
Nelson A, Kaltenbach L, McGuire D, Levya M, Al-Khalidi H, Webb L, et al.
Am Heart J
. 2024 Dec;
282:51-57.
PMID: 39716628
Background: SGLT-2i and GLP-1RA are recommended for persons with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD); for those prescribed, little is known about reasons for discontinuation. Methods: From the...
8.
Harrington J, Kang Y, McGuire D
Diabetes Care
. 2024 Oct;
47(11):1897-1899.
PMID: 39432776
No abstract available.
9.
Selvaraj S, Patel S, Sauer A, McGarrah R, Jones P, Kwee L, et al.
Circ Heart Fail
. 2024 Oct;
17(11):e011980.
PMID: 39421941
Background: Mechanisms of benefit with SGLT2is (sodium-glucose cotransporter-2 inhibitors) in heart failure (HF) remain incompletely characterized. Dapagliflozin alters ketone and fatty acid metabolism in HF with reduced ejection fraction though...
10.
Harrington J, McGuire D, Inzucchi S
JACC Heart Fail
. 2024 Oct;
12(11):1827-1829.
PMID: 39387772
No abstract available.